- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01396642
Topical Emollient Therapy
Effect of Topical Emollient Therapy on Clinical Outcomes in Preterm Neonates - A Clinical Trial
Almost all (99%) of the neonatal deaths occur in lower and middle income countries. Most of these deaths are attributable to prematurity and infection. With the increasing rate of premature births in some settings, the mortality rate of over 50% among preterm babies in some of the developing countries require inexpensive hospital-based strategies to prevent fatal infections in newborns of these countries. As most of the deaths in preterm neonates are attributable to their vulnerability of infection, a potential low cost intervention like topical emollient therapy can be effectively directed to reduce infection related mortality and morbidity in the developing countries. Topical emollient therapy reduces the rate of infection by enhancing the skin barrier function, thus reducing trans-epidermal water loss consequently conserving heat and energy to promote growth.
The broad goal of the study is to improve the survival rate of hospitalized preterm neonates in the developing countries by decreasing the incidence of infection using low-cost interventions.
HYPOTHESIS:
It is hypothesized that topical emollient therapy with coconut oil twice a day till 28th day of life in hospitalized preterm neonates reduces the incidence proportion of hospital acquired infection by 40% 15 as compared to routine skin care. For the secondary objective it is hypothesized that the weight gain in the neonates receiving prophylactic application of emollient, which is coconut oil twice a day till 28th day of life, is at least 2g/kg/day18 more as compared to the weight gain in the routine skin care group.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Research question:
- The primary research question to be addressed via this study is whether the prophylactic application of emollient, which is coconut oil twice a day till 28th day of life, effective in reducing the incidence proportion of hospital acquired infection among preterm neonates by 40% as compared to the routine skin care.
- The secondary research question is whether the weight gain in the neonates receiving prophylactic application of emollient, which is coconut oil twice a day till 28th day of life, is at least 2g/kg/day more as compared to the weight gain in the routine skin care group.
Objectives: This study has the following primary objectives:
To evaluate the effectiveness of topical emollient in preventing hospital acquired infection in preterm neonates.
The secondary objective is:
- To compare the weight gain among the two groups of neonates.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan, 74800
- The Aga Khan University
-
Karachi, Sindh, Pakistan
- The Aga Khan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Any preterm neonates (>26 weeks and < 37 weeks of gestation by maternal dates)
- Birth weight of at least 750 gm
- Age ≤72 hours of life
- Baseline blood cultures obtained
- Expected survival > 48 hours (based on the clinical judgment by the physicians)
Exclusion Criteria:
- Neonate with severe RDS on admission as declared by the consulting Physician on the basis of radiologic findings.
- Neonate within first 24 hours of critical care
- Life threatening congenital anomalies
- Congenital skin anomalies
- Hydrops Fetalis
- Congenital infection of the skin
- History of any previous treatment with the ointment
- Newborns admitted for major surgical procedure with expected high rates of infectious complications.
- Newborns with positive baseline blood cultures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Topical Emollient
Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
|
Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
|
No Intervention: Routine Skin Care
Neonates in this group will receive routine skin care as per unit protocol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital Acquired Blood Stream Infection
Time Frame: 28 days of life
|
Hospital Acquired Infection is defined as a blood culture positive for any organism in a neonate with baseline negative cultures on admission.
|
28 days of life
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Weight Gain
Time Frame: 28th Day of Life
|
28th Day of Life
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zulfiqar ZB Bhutta, MBBS, PhD, The Aga Khan University
- Principal Investigator: Rehana A Salam, MSc, The Aga Khan University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1258-CHS/ERC-09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Stream Infection
-
Fresenius KabiCompleted
-
Assiut UniversityUnknownBlood Stream InfectionEgypt
-
Ain Shams UniversityCompletedCatheter Related Blood Stream Infection
-
Geert WantenGeistlich Pharma AGCompletedCatheter Related Blood Stream InfectionsUnited Kingdom, Israel, Denmark, Germany, Italy, Netherlands
-
University of CologneCompletedCLABSI - Central Line Associated Bloodstream Infection | Catheter-Related Blood Stream InfectionGermany
-
University of MichiganCompletedPneumonia | Blood Stream InfectionUnited States, Israel, Thailand, Greece, Bulgaria, Italy, Taiwan
-
Tan Tock Seng HospitalMayo ClinicUnknownSepsis | Fungemia | Bacteremia | Blood Stream InfectionSingapore
-
Beaumont HospitalUnknownCentral Line Infection | Hemodialysis Catheter Blood Stream Infection | Dialysis Line ThrombosisIreland
-
The First Affiliated Hospital of Soochow UniversityRecruitingAcute Myeloid Leukemia | Gut Microbiota | Blood Stream InfectionChina
-
Institute of Tropical Medicine, BelgiumKU Leuven; Institut National de Recherche Biomédicale. Kinshasa, République... and other collaboratorsCompletedBlood-stream Infections | Salmonella Infection Non-TyphoidCongo, The Democratic Republic of the
Clinical Trials on Topical Emollient
-
Regeneron PharmaceuticalsSanofiRecruitingModerate-to-Severe Atopic Dermatitis | Atopic EczemaUnited States
-
Promius Pharma, LLCCompleted
-
Stanford UniversityUniversity of California, San Francisco; University of ZimbabweNot yet recruiting
-
International Centre for Diarrhoeal Disease Research...GlaxoSmithKline; Stanford UniversityCompletedMalnutrition | Malnutrition in Children | Child MalnutritionBangladesh
-
Regeneron PharmaceuticalsSanofiCompletedStudy to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)Atopic Dermatitis (AD)United States, Canada
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSexually Transmitted InfectionsKenya
-
Reckitt Benckiser Healthcare (UK) LimitedSkin Investigation TechnologyCompleted
-
Galderma Brasil Ltda.Completed
-
Clinical Life Sciences Ltd.Completed
-
Oslo University HospitalCompleted